@entity295 precipitates a systemic inflammatory stimulus that causes systemic release of cytokines and sequestration of polymorphonuclear neutrophils, resulting in degranulation of matrix metalloproteinases (MMPs), which causes extracellular matrix basement membrane degradation. One of the important anti-inflammatory properties of tetracyclines is their ability to inhibit MMPs. In this study, we focused on the regulation of MMPs in @entity295 and their reduction by treatment with nonantimicrobial chemically modified tetracyclines (CMTs), which retain their anti-inflammatory activity. @entity295 was induced by @entity1588 ( @entity1588 ) method. At 24 h and 1 h before @entity1588 , some @entity35 received @entity33954 (25 mg/kg), another group of @entity35 received hydroxamate (H; an inhibitor of @entity70040 mg/kg), and untreated @entity35 received saline by gavage. At 0 h, 0.5 h, 1.5 h, and 24 h after @entity1588 , blood and liver samples were collected. Plasma and liver @entity6929 by zymography and Western immunoblotting, plasma nitric oxide by measuring nitrate level, plasma glutamic oxaloacetic transaminase (GOT) and @entity4749 ( @entity4749 ) by enzymatic method, and liver gelatinase by radiolabeled gelatin lysis assay and 24 h mortality were determined. Plasma @entity6929 (92 kDa), nitrate, and GOT and @entity4749 levels were elevated compared with the time 0 level and reached peak at 1.5 h @entity1588 and remained high for 24 h. Both @entity33954 and H treatment reduced GOT, @entity4749 , @entity6929 , and nitrate levels throughout the 24 h. @entity33954 and H are equally effective in @entity295 treatment. The 24-h mortality for @entity1588 @entity35 was 30%, whereas pretreatment with @entity33954 and H resulted in 0% mortality. Hepatic @entity6929 and gelatinase activity increased significantly after @entity1588 , and pretreatment with @entity33954 and H inhibited these expressions. These results indicate the beneficial effect of @entity33954 in preventing the increase in GOT, @entity4749 , NO, @entity6929 , gelatinase activity, and the ensuing @entity326 .

Inhibition of matrix metalloproteinases by chemically modified tetracyclines in XXXX .

@entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis', 'Sepsis'] @entity33954 :: ('MESH:C537989', 'Disease') :: ['CMT-3'] @entity4749 :: ('81670(Tax:10116)', 'Gene') :: ['glutamic pyruvic transaminase', 'GPT'] @entity326 :: ('MESH:D012772', 'Disease') :: ['septic shock'] @entity1588 :: ('MESH:D002429', 'Disease') :: ['CLP', 'cecal ligation and puncture'] @entity6929 :: ('81687(Tax:10116)', 'Gene') :: ['MMP-9', '92-kDa gelatinase'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity70040 :: ('302963(Tax:10116)', 'Gene') :: ['MMP; 25']
@entity295 :: (MESH:D018805,Disease) :: ['sepsis']
